Onkologie. 2011:5(1):30-33

Options of prevention in BRCA1 and BRCA2 mutation carriers

Jan Novotný1,2, Martina Zimovjanová1
1 Onkologická klinika VFN a 1. LF UK, Praha
2 Onkologické oddělení Nymburk

BRCA1 and BRCA2 mutation carriers have substantial risk of breast and ovarian cancer development. To decrease this risk, various

surgical and nonsurgical primary prevention procedures are currently offered at specialized institutions. Among them, prophylactic

bilateral salpingooophorectomy and prophylactic mastectomy are used most frequently. The other include chemoprevention and the

modification of life style habits.

Keywords: BRCA1, BRCA2, breast cancer, ovaria cancer, prevention

Published: February 25, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novotný J, Zimovjanová M. Options of prevention in BRCA1 and BRCA2 mutation carriers. Onkologie. 2011;5(1):30-33.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Novotvary 2007, ÚZIS ČR, NOR ČR 2010, ISSN 1210 857X, ISBN 978-80-7280-849-6.
    2. Chen S, Parmigiani G. Meta-Analysis of BRCA1 and BRCA2 Penetrance. J Clin Oncol 2007; 25: 1329-1333. Go to original source... Go to PubMed...
    3. Weischer M, Bojensen SE, Ellervik C, et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk. Meta-analyses of 26000 patient cases and 27000 controls. J Clin Oncol 2008; 26: 542-548. Go to original source... Go to PubMed...
    4. Kurian AW, Sigal BM, Plevritis SK. Survival Analysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers. J Clin Oncol 2010; 28: 222-231. Go to original source... Go to PubMed...
    5. Meijers-Heijboer H, van Geel B, van Putten WLJ, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159-164. Go to original source... Go to PubMed...
    6. Graeser MK, Engel Ch, Rhiem K, et al. Contralateral Breast Cancer risk in BRCA1 and BRCA2 Mutation Carriers. J Clin Oncol 2009; 27: 5887-5892. Go to original source... Go to PubMed...
    7. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of Risk Reduction estimates Associated With Risk-Reducing Salpingooophorectomiy in BRCA1 and BRCA2. J Natl Canc Inst 2009; 101: 80-87. Go to original source... Go to PubMed...
    8. Domchek SM, Friebel T, Neuhausen SL, et al. Mortality afterbilateral salpingooophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006; 7: 223-229. Go to original source... Go to PubMed...
    9. Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 2007; 7: 702-707. Go to original source... Go to PubMed...
    10. Roukos DH, Briasolis E. Individualized preventive and therapeutic management of hereditary breast and ovarian cancer syndromes. Nature Clinical Practice 2007; 4: 578-590. Go to original source... Go to PubMed...
    11. King MC, et al. Tamoxifen and breast cancer incidence amnog women with inhereted mutations in BRCA1/2 carriers: NSABP P01 trial. JAMA 2001; 286: 2251-2256. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.